OST-HER2
Osteosarcoma (HER2+)
Phase 1Active (Clinical trials ongoing)
Key Facts
About OS Therapies
OS Therapies is a mission-driven, clinical-stage oncology company developing breakthrough treatments for cancers with high unmet need, starting with osteosarcoma. Its strategy leverages a dual-technology approach: a novel HER2-targeted immunotherapy designed to induce broad anti-tumor immune responses and a proprietary tunable ADC platform for precision oncology. The company has initiated its first clinical trial, gained significant public and media attention including Emmy-nominated documentary coverage, and is led by a team with deep biopharma and capital markets experience.
View full company profile